Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. - Wikidata - awgldk - TriplyDB

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q35042489

about

Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study Biomarkers of World Trade Center particulate matter exposure: physiology of distal airway and blood biomarkers that predict FEV1 decline Epithelial Anion Transport as Modulator of Chemokine Signaling Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing levels of disease severity Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease.Potential prognostic value of biomarkers in lavage, sputum and serum in a five year clinical follow-up of smokers with and without COPD Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and Activation-Regulated Chemokine)Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease.Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.The relation of serum myeloperoxidase to disease progression and mortality in patients with chronic obstructive pulmonary disease (COPD).Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.Clinical update on the use of biomarkers of airway inflammation in the management of asthma.COPD association and repeatability of blood biomarkers in the ECLIPSE cohort.Analysis of the plasma proteome in COPD: Novel low abundance proteins reflect the severity of lung remodeling.The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease Fetuin-B (FETUB): a Plasma Biomarker Candidate Related to the Severity of Lung Function in COPD Challenges with QuantiFERON-TB Gold assay for large-scale, routine screening of U.S. healthcare workers.Club cell protein 16 and disease progression in chronic obstructive pulmonary disease.Biomarkers of therapeutic response in patients with chronic obstructive pulmonary disease: a critical review of the literature.Unifying thoracic biomarkers: surfactant protein-D and beyond.Update in chronic obstructive pulmonary disease 2011.Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease.The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease.Blood specimen biomarkers of inflammation, matrix degradation, angiogenesis, and cardiac involvement: a future useful tool in assessing clinical outcomes of COPD patients in clinical practice?Role of CCL18 in asthma and lung immunity.Lessons from ECLIPSE: a review of COPD biomarkers.Biomarkers, the control panel and personalized COPD medicine.Subtyping Chronic Obstructive Pulmonary Disease Using Peripheral Blood Proteomics.The use of cellular and molecular biomarkers to manage COPD exacerbations.Prediction and prevention of exacerbations and mortality in patients with COPD.An ECLIPSE View of Alpha-1 Antitrypsin Deficiency.A systemic defect in Toll-like receptor 4 signaling increases lipopolysaccharide-induced suppression of IL-2-dependent T-cell proliferation in COPD.Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization.

P2860

Q23910631-7929C472-0F09-4721-B6B7-3C7A812540EF Q23918414-98239EFA-2CFC-4AD4-B4D5-312D0AE5EDF6 Q26744381-9B8D440F-8B33-47BF-8C21-D1744B913BF8 Q26766294-12A987CB-FF8B-4BDC-B671-FE703096F73D Q28650506-7F45402A-8A14-48BC-B280-28C578A5D62C Q28728578-9DC87426-1A9F-403D-9AF5-D1AB538E1203 Q28728826-BF7B986F-B076-40D2-BDFF-E334FF7260E5 Q33586131-BDCCCADA-9F02-4563-AAF8-DA6F732C3C9D Q33612752-6E241094-BE71-496F-B56B-6D337E7BC5CD Q33703730-51278DF3-0B0B-4969-BAD8-D7D3B17E6E27 Q33705867-0707BE0D-4F0B-435C-BCE0-6B78700C3578 Q34636461-B867F56B-0B56-465C-B876-3585F5BDE011 Q34700195-C31EEEE1-13EB-40E0-BD78-D1BD0B59E928 Q35077055-18D3D7EA-2D13-47A5-9838-D55DA57381E8 Q35117838-623D4F65-7ED1-4271-8C7E-BB0367B0EB07 Q35637295-DD40A198-0334-4801-9535-2185BC8DBC98 Q35835036-083A7F16-95B1-42E6-98CE-9FBEC13E702A Q36288980-935E7F81-2AA5-4CD7-A1AC-90496572709C Q36300138-AFE071AB-FA4D-4C24-8C04-CD886269F70E Q36383938-0FE02095-2CC9-4BE3-8373-6F3C8400BF5B Q36468155-96C3B2E1-BF5F-4ADD-BD0B-36642BB29C60 Q37012728-3FE0EC42-C279-4034-88CC-DD64F293ECCE Q37117439-80CD48C2-391F-40A3-83EB-CAF0CEBF6A4B Q37304401-0AAB1AF5-360E-472A-B508-3F40E40F51A9 Q37566520-77EFAC5C-941E-45B2-B169-0BB7FAEB6BCA Q37937720-051B906A-B77E-47A9-92B3-74C49051DE41 Q37997815-D98B3FC4-3166-4099-A4BB-7A4318811352 Q38015786-59289D76-9D0F-443E-AA1B-F87799372B30 Q38056532-B6F1EEC1-C6C2-4109-BB07-9DB46281460B Q38077797-4F84C837-6E28-4443-91EB-6B5951FED854 Q38109057-F822CBEC-33D0-438C-9840-99DFD78123D2 Q38115809-C3264739-53EB-4119-A708-065B98428DC8 Q38169066-07027769-58CB-4C25-8D0F-D02994D3FD87 Q38546748-3DF282AF-DF12-42FB-BEDF-2E00F48D1132 Q38604607-21BA756F-0658-43C2-9CD8-49BBC8BA11DB Q38739067-2C4FD6E3-559C-4128-809C-C617AFAB48C8 Q38823010-FD50FCAF-8B27-4B06-B540-A6D3D5ECC006 Q38937853-B1CEDBC6-4496-4CEF-9685-8DE421755096 Q40938504-E5D95662-DBA8-42D4-934F-66873C5FB819 Q41020098-B52A2831-8D07-4FB2-BBC2-21A6E3F5E483

P2860

Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease.

http://www.wikidata.org/entity/Q35042489

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Serum PARC/CCL-18 concentratio ...... obstructive pulmonary disease.

@en

type

label

Serum PARC/CCL-18 concentratio ...... obstructive pulmonary disease.

@en

prefLabel

Serum PARC/CCL-18 concentratio ...... obstructive pulmonary disease.

@en

P1433

Q35042489-7E345401-ECDF-41CF-A8B8-85BE92EEE477

P1476

Q35042489-A1C667F4-03AA-48E1-86B6-4066D58F8616

P2093

Q35042489-0277E9CF-E561-4A04-83CB-66D53EE4982F

Q35042489-0CC0BAA5-37B2-4973-9CD5-A8208106F51F

Q35042489-1C27F904-63D0-439F-9F7C-55FC49B280D6

Q35042489-243CE9A5-DA82-43B5-B629-83D3ED30CF79

Q35042489-3E442D6B-73C0-42AB-9269-777F084746E9

Q35042489-44151C06-2829-4B00-B78C-669A5B06EEF6

Q35042489-7F56EB8D-A369-4974-A0D2-49D1BE02CF16

Q35042489-8FFF1BC2-CB3D-4D35-B689-1581D2062950

Q35042489-A1646FFE-7804-4071-86D5-AC1ED79F7356

Q35042489-B0EE642B-414C-4FAB-B9CE-70AEA0FD9F58

P2860

Q35042489-039168C4-71DA-4C92-A6C0-1BE205635B7F

Q35042489-0E1E475D-DDBC-45E1-82D6-46679016AFBC

Q35042489-213A006A-8BA6-4D23-A2FF-4A442428EA68

Q35042489-28ED893F-3A83-4FED-ADAC-1C5B8B411FD2

Q35042489-30C25359-4B23-4A8F-99E7-7DFEADFC8918

Q35042489-32B54D89-A5E0-405A-AF2F-7BB56B2ECC39

Q35042489-43324785-B5EB-4C11-B0F5-5746175D2DE6

Q35042489-66A35C84-6FF0-477D-8BFA-C6B72E188213

Q35042489-869AB813-7A70-4331-92DC-DD8FE3E67766

Q35042489-8B961848-EBBF-4A36-8138-55A99DB7AE5B

P304

Q35042489-C1BE2D66-4EE1-4D17-92AE-2942B9A22792

P31

Q35042489-D111FE7F-1667-4CAF-B121-94BC8D33D17D

P356

Q35042489-F40340C4-5665-45F0-92D5-A344A08AB3A8

P407

Q35042489-626FFF94-9332-417D-BE72-43716DB2E9A1

P433

Q35042489-CBDC550C-6E4C-473D-B7BE-A029A2D40B6B

P478

Q35042489-A2A4070C-66B3-4559-82C2-790E5A3EDFCE

P50

Q35042489-8130A7CD-C538-4443-904E-C42F67B87B66

Q35042489-BBD24202-12B1-40F0-82B5-BB1154F6471A

Q35042489-E0375D35-968F-4728-9484-E59555583201

Q35042489-E088C57B-659F-4919-97B4-0BCEA4A74C00

P577

Q35042489-DF1B0E7E-83A7-434E-9AE5-B1A9B2ADED06

P698

Q35042489-8A1E95D3-D4D0-4125-AF46-8EB46C205D9D

P921

Q35042489-D39AEEF8-4234-47CB-9DAC-3DFB65A66850

P932

Q35042489-34231F7B-E3DF-4B3E-995C-ACC6C9B44145

P356

RCCM.201008-1220OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Serum PARC/CCL-18 concentratio ...... obstructive pulmonary disease.

@en

P2093

Annelyse Duvoix

http://www.w3.org/2001/XMLSchema#string

Bartolome R Celli

http://www.w3.org/2001/XMLSchema#string

Bruce E Miller

http://www.w3.org/2001/XMLSchema#string

David A Lomas

http://www.w3.org/2001/XMLSchema#string

Don D Sin

http://www.w3.org/2001/XMLSchema#string

Donald Tashkin

http://www.w3.org/2001/XMLSchema#string

ECLIPSE Investigators

http://www.w3.org/2001/XMLSchema#string

Edwin K Silverman

http://www.w3.org/2001/XMLSchema#string

John E Connett

http://www.w3.org/2001/XMLSchema#string

Lisa D Edwards

http://www.w3.org/2001/XMLSchema#string

P2860

A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells

A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1 alpha/LD78 alpha and chemotactic for T lymphocytes, but not for monocytes

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.

PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia.

Biomarkers and surrogate markers: an FDA perspective.

Profiling serum biomarkers in patients with COPD: associations with clinical parameters

Expression and regulation of CCL18 in synovial fluid neutrophils of patients with rheumatoid arthritis.

P304

1187-1192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201008-1220OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

183

http://www.w3.org/2001/XMLSchema#string

P50

Ruth Tal-Singer

P577

2011-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21216880

http://www.w3.org/2001/XMLSchema#string

P921

chronic obstructive pulmonary disease

P932

3114051

http://www.w3.org/2001/XMLSchema#string